In March 2026, Decoy established an AI collaboration with Quantori and Google Cloud to boost computational peptide design capacity by 25–100× and in February was named a Hello Tomorrow Deep Tech Pioneer. In January it secured a Global Access Commitment with the Gates Foundation for scalable, low-cost antiviral manufacturing and launched a robust investor relations and social media strategy to enhance visibility.

The proprietary IMP³ACT™ platform integrates AI-driven design, machine learning and rapid peptide-conjugate synthesis to reduce drug development from years to months. Its D-MAV approach targets conserved viral mechanisms across multiple pathogens, enabling single therapeutic candidates to address diverse viruses, and supports scalable “single-shot” processes to expedite design-build-test-learn cycles.

Decoy’s lead DCOY-COV pan-coronavirus candidate has demonstrated broad in-vitro activity against known human coronaviruses and is backed by non-dilutive funding, with a Phase 1 clinical trial expected in 2027. The DCOY-TRI program targets influenza, coronavirus and paramyxoviruses (including RSV), potentially addressing 55–70% of respiratory infections annually with early data showing multi-family antiviral activity.

The company plans lead candidate selection and IND-enabling studies later this year, followed by filings or international equivalents and first-in-human trials, potentially leveraging human challenge studies to compress timelines. Continued presentations of preclinical and translational data and pursuit of strategic partnerships are expected to drive near-term value inflection.